NuGenerex Immuno-Oncology Announces Board of Directors

- Renowned leaders in biotechnology, pharmaceuticals, oncology, operations and finance to provide guidance to management team
- NuGenerex Immuno-Oncology (NGIO) is focused on modulation of the immune system to develop Ii-Key peptide vaccines for the treatment and prevention of cancer and infectious diseases
- NGIO is now a stand-alone public company with plans to list shares on Nasdaq

MIRAMAR, Fla., July 01, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology is pleased to announce the Board of Directors who will help lead the company’s strategic plans to build a world-class immune-oncology organization. The Board is comprised of renowned leaders in the fields of oncology, biotechnology and pharmaceutical development, sales and marketing, operations, and finance. These highly regarded professionals will provide expertise and guidance to the NGIO management team as the company takes the final steps toward the listing of the NGIO shares on Nasdaq and the implementation of the NGIO strategic & operating plans. The board, whose biographies are presented herein, include internal members Joseph Moscato (Chairman), Anthony Crisci, Esq., CPA (Corporate Counsel & Chief Legal Officer) and Richard Purcell (Executive Vice President of R&D), as well as independent Directors Dr. Craig Eagle, MD, Dr. Marvin Hausman, MD, Carol Nacy, PhD, S. Gail Eckhardt, MD, Thomas Leonard, MPA, and Brian T. McGee.

Joseph Moscato. Mr. Moscato is currently the Chief Executive Officer, President, and Chairman of the Board for Generex since January 2017.  Mr. Moscato has over 30 years of experience in healthcare, sales and marketing, distribution management, and finance.  Mr. Moscato brings his marketing and advertising acumen to drug discovery and diagnostic & treatment development and commercialization.  Since 2009, working as an exclusive consultant to the company, Mr. Moscato has originated and negotiated several licensing deals, advised on equity financings, and implemented the broad strategic vision for the Company.  Mr. Moscato has worked and consulted for Pfizer in several capacities from sales and marketing to new drug discovery & development to licensing.